This review looked at the effects of low-or mini-dose warfarin, compared with a regimen where the warfarin dose was adjusted to a target International Normalised Ratio (INR), in people with non-rheumatic atrial fibrillation. The risk of thromboembolic events was higher with low-or mini-dose warfarin. The review appears to have been well conducted and the conclusions are supported by the data presented.
To assess the effects of reduced-dose (low-dose or mini-dose) anti-vitamin K therapy, compared with an adjusted dose, in people with atrial fibrillation.
Searching
MEDLINE was searched from 1983 to August 2002; the search terms were reported. The bibliographies of relevant identified papers were checked, and authors and experts were contacted for any unpublished studies. No language restrictions were applied.
Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion.
Specific interventions included in the review
Studies that investigated the effects of low-dose warfarin were eligible for inclusion. In the included studies, the reported fixed low dose ranged from 0.5 to 3 mg/day. The comparator groups received adjusted-dose warfarin. The target International Normalised Ratio (INR) was 1.1 to 1.6 for the low dose and 2 to 3.5 for the adjusted dose. Concomitant aspirin was given in some studies.
Participants included in the review
Studies of people with non-rheumatic atrial fibrillation were eligible for inclusion. The participants in the included studies had non-valvular chronic, recurrent or intermittent atrial fibrillation. In one study the participants had additional risk factors (prior stroke, transient ischaemic attack or systemic embolism, systolic blood-pressure over 160 mmHg, or impaired left ventricular function). In other studies people with these higher risk factors were excluded, as were people with mitral stenosis or prosthetic cardiac valves, myocardial infarction, pacemaker, cardiomyopathy, chronic heart failure, mitral incompetence and, in one study, people over 78 years. The mean age of the participants ranged from 72 to 75 years.
Outcomes assessed in the review
Studies that reported thromboembolic events were eligible for inclusion. The outcomes reported include ischaemic stroke, systemic embolism, transient ischaemic attack, a combined outcome of thromboses (ischaemic stroke, systemic embolism or myocardial infarction), vascular death, major haemorrhage and haemorrhagic death. The definitions for these outcomes were those used in the included studies. In all studies stroke was diagnosed by a computerised tomographic scan.
How were decisions on the relevance of primary studies made?
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.
